Caris Life Sciences, Irving, Texas, has launched MI Exome, a next-generation sequencing-based assay analyzing the whole exome of 22,000 DNA genes. MI Exome joins the Caris Molecular Intelligence suite of comprehensive profiling services that are designed to detect and characterize the molecular features of cancer to guide more precise individualized treatment decisions for patients.

David Spetzler, MBA, PhD, Caris Life Sciences.

David Spetzler, MBA, PhD, Caris Life Sciences.

“Whole-exome sequencing with MI Exome will be run on every patient and will deliver unprecedented detail into the genomic characteristics of cancers, which will greatly improve our ability to understand the disease and provide insights needed to help physicians and patients make more informed treatment decisions that improve outcomes,” says David Spetzler, PhD, MBA, president and chief scientific officer of Caris Life Sciences. “Combined with our whole-transcriptome sequencing and proteomic testing, as well as our advanced artificial intelligence and machine-learning capabilities, Caris provides the most comprehensive and informative molecular profile for cancer patients in a clinical offering that’s ever been available.”

For more information, visit Caris Life Sciences.